Cardiff Oncology, Inc.
CRDF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRDF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRDF
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop therapies for RAS-mutated metastatic colorectal cancer and other high-need oncology indications.
Key risk: Cash runway limited
BioSniper Score
Based on 6 of 6 signals
Market Cap
$73.1M
Cash Runway
7.0 moLead Asset
Onvansertib (Onv) (Phase 2)Next Catalyst
Phase3_Topline · Oct 1, 2032Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for Cardiff Oncology, Inc..
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop therapies for RAS-mutated metastatic colorectal cancer and other high-need oncology indications.
- Clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers [sec_mda · as of 2026-02-24].
- Focusing clinical programs in RAS-mutated metastatic colorectal cancer (mCRC) and investigator-initiated trials in mPDAC, SCLC, mTNBC, and Chronic [sec_mda · as of 2026-02-24].
- Cash, cash equivalents and short-term investments of $34.5 million as of June 30, 2026, with working capital of $24.8 million [sec_mda · as of 2026-08-11].
- Completed a registered direct offering on July 14, 2026, generating gross proceeds of approximately $10.1 million [sec_mda · as of 2026-08-11].
- Net losses and negative operating cash flows since inception; expects to continue incurring losses and require additional capital [sec_mda · as of 2026-05-14].
What works
- Leverages a well-validated oncology drug target (PLK1 inhibition) with a pipeline addressing multiple high-unmet-need cancers [sec_mda · as of 2026-02-24].
- Lead program onvansertib is being evaluated in combination with standard-of-care therapeutics, potentially offering a differentiated treatment approach [sec_mda · as of 2026-02-24].
- Completed a $10.1 million registered direct offering in July 2026, providing additional near-term capital [sec_mda · as of 2026-08-11].
What to weigh
- Cash and short-term investments of $34.5 million as of June 30, 2026, with working capital declining from $43.7 million at December 31, 2025 [sec_mda · as of 2026-08-11].
- Incurred net losses since inception and has negative operating cash flows; expects to require additional capital for the foreseeable future [sec_mda · as of 2026-05-14].
- Drug development efforts are in early stages with high uncertainty regarding costs, timelines, and regulatory approval [sec_mda · as of 2026-08-11].
- Capital resources as of March 31, 2026 were expected to fund operations only into the first quarter of 2027, not sufficient for at least 12 months [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
Company is a clinical-stage biotechnology company leveraging PLK1 inhibition.
“We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need.”
SEC filings · February 24, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had $34.5 million in cash, cash equivalents and short-term investments.”
SEC MD&A · August 11, 2026
Company has incurred net losses since inception and expects to continue.
“We have incurred net losses since our inception and have negative operating cash flows.”
SEC MD&A · August 11, 2026
Capital resources expected to fund operations only into Q1 2027.
“Based on our current projections, we expect that our capital resources are sufficient to fund our operations into the first quarter of 2027, which is not sufficient to meet our funding requirements for at leas”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2032-10-01 · Phase3_Topline · zipalertinib — Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Pl — Topline data from a Phase 3 study of zipalertinib will be reported, which may inform the drug's efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash and investments of $34.5M as of June 30, 2026 may only fund operations into Q1 2027 [sec_mda · as of 2026-08-11].
- Early-stage pipeline — Drug development is in early stages with high uncertainty in costs, timelines, and regulatory approval [sec_mda · as of 2026-08-11].
- Need for additional capital — Company expects to continue incurring losses and will require additional capital; may not be available on acceptable terms [sec_mda · as of 2026-05-14].
- Dilution risk — Raising funds by issuing equity securities may cause additional dilution to stockholders [sec_mda · as of 2026-05-14].
What to watch
- Cash burn rate and any additional financing activities, especially after the July 2026 offering [sec_mda · as of 2026-08-11].
- Clinical trial progress for onvansertib in RAS-mutated mCRC and other indications [sec_mda · as of 2026-02-24].
- FDA interactions and potential registrational trial design agreements for onvansertib [sec · filed 2025-04-29].
- Upcoming catalyst: Phase 3 topline data for zipalertinib on 2032-10-01 [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Cardiff Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cardiff Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
7.0 months
D/E 0.41 · 0% dilution
Lead: Phase 2
1 candidate
1 upcoming, next in ~2224d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
113
Total value held
$39.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,711,932 | $9.3M |
| blackrock, inc. | 3,981,387 | $6.4M |
| laurion capital management lp | 2,646,738 | $4.3M |
| acorn capital advisors, llc | 1,762,084 | $2.9M |
| geode capital management, llc | 1,599,663 | $2.6M |
| franklin resources inc | 1,205,803 | $2.0M |
| state street corp | 1,186,947 | $1.9M |
| flputnam investment management co | 595,127 | $964K |
| northern trust corp | 493,205 | $799K |
| vanguard fiduciary trust co | 446,225 | $723K |
Showing top 10 of 113 institutional holders of Cardiff Oncology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 27.5%
- Days to cover
- 25.5
- Shares short
- 18,374,168
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRDF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cardiff Oncology, Inc.?
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop therapies for RAS-mutated metastatic colorectal cancer and other high-need oncology indications.
What is Cardiff Oncology, Inc.'s lead drug candidate?
Cardiff Oncology, Inc.'s most advanced tracked candidate is Onvansertib (Onv) (Phase 2) for Metastatic Colorectal Cancer; Recurrent Chronic Myelomonocytic Leukemia.
What is Cardiff Oncology, Inc.'s next catalyst?
Cardiff Oncology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Pl" — expected October 1, 2032.
Who is the CEO of Cardiff Oncology, Inc.?
Dr. Mani Mohindru Ph.D. is the chief executive officer of Cardiff Oncology, Inc. (CRDF).
Where is Cardiff Oncology, Inc. headquartered?
Cardiff Oncology, Inc. (CRDF) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.